CICC (03908): The coupon rate for "24 Zhongjin G1" is lowered by 84 basis points in the next 2 years.
CICC (03908) announced that, according to the provisions of the prospectus for the public issuance of corporate bonds for professional institutional investors by China International Finance Limited Company in 2024, China International Finance Limited Company ("the Company") has the right to decide at the end of the second year of the "24 CICC G1" (hereinafter referred to as "this bond") whether to adjust the coupon rate for the subsequent interest period of this bond.
CICC (03908) announced that, according to the "China International Finance Corporation Limited 2024 Open Issue of Corporate Bonds (First Tranche) for Professional Institutional Investors Prospectus," China International Finance Corporation Limited (referred to as the "Company" or "Issuer") has the right to decide at the end of the second year of the term of the "24 CICC G1" bonds (referred to as the "current bond") whether to adjust the face interest rate for the subsequent interest periods of the current bond. Based on the actual situation of the Company and the current market environment, the Company has decided to reduce the face interest rate for the next two years of the current bond by 84 basis points, meaning that from March 4, 2026 to March 3, 2028, the face interest rate of the current bond will be 1.55% (the current bond applies annual simple interest, not compound interest).
Related Articles

Surge in memory prices impacts Apple Inc.'s profits, its financial report will become an industry "stress test" indicator.

ECO-TEK HLDGS (08169) announced its annual performance. The company's attributable loss is approximately HK$2.868 million, an increase of 58.8% year-on-year.

CSPC PHARMA (01093): SYS6055 injection approved for clinical trials in China.
Surge in memory prices impacts Apple Inc.'s profits, its financial report will become an industry "stress test" indicator.

ECO-TEK HLDGS (08169) announced its annual performance. The company's attributable loss is approximately HK$2.868 million, an increase of 58.8% year-on-year.

CSPC PHARMA (01093): SYS6055 injection approved for clinical trials in China.

RECOMMEND

Late‑Night Broad Rally As Chip Sector Receives Major Boost: Price Hikes Announced
29/01/2026

Embodied Intelligence: From Frenzy To Breakthrough Through Real‑World Deployment
29/01/2026

Dollar Falls To Four‑Year Low, Trump “Adds Fuel To The Fire”: Not Worried, Dollar Performing Well, Will Find A Reasonable Level
29/01/2026


